Gabapentin and pregabalin bind to the alpha-2-delta calcium channel subunit and represent a novel analgesic drug class. The evidence base supporting their use for chronic neuropathic and early postsurgical pain is reviewed.
Introduction
Two anticonvulsants, gabapentin and pregabalin, have been studied as treatments for a wide variety of disorders including pain [1], epilepsy [2], spasticity [3] and anxiety [4] . The basic and clinical pharmacology of these drugs has become an intense field of research. Simple MED-LINE searches of these drugs in May 2007 have yielded more than 2500 citations, 200 randomized controlled trials (RCTs) and, in the area of pain management alone, over a dozen systematic reviews and meta-analyses (see Table 1 ). Furthermore, recent searches on 'www. clinicaltrials.gov' and 'www.controlled-trials.com' show over 70 ongoing trials. In the dynamic setting of ongoing research, this article attempts to provide an up-to-date evidence-based qualitative review that delineates the evolving role of gabapentin and pregabalin in treating chronic neuropathic and early postsurgical pain. The reader should keep in mind possible limitations of such a review of published evidence, which include heterogeneity across studies with respect to quality, design and outcome measures, as well as the potential for publication bias since many 'negative' trials are not published and may even stay out of the public domain [17] .
A literature search was conducted using the Cochrane Central Register of Controlled Trials (2007, Issue 2) and the MEDLINE Database (1966 to May 2007). All RCTs were evaluated by the author of this review and rated using a three-item (1-5) quality scale [18] .
Historical perspective
In 1977, gabapentin (Neurontin [1-(aminomethyl)cyclohexaneacetic acid]) -an alkylated analogue of gammaaminobutyric acid (GABA) -was synthesized [19] and subsequently developed as an anticonvulsant drug in the late 1980s [20] . Initial interest in the potential of gabapentin as an analgesic drug was stimulated by early case reports in neuropathic pain in the mid 1990s [21] [22] [23] , which led to more formal pain investigations concurrently conducted in both laboratory [24, 25] and clinical [26, 27] settings. Pregabalin (Lyrica [(S)-(þ)-3-(aminomethyl)-5methylhexanoic acid]) is a pharmacologically similar alkylated GABA analogue that was synthesized over a decade after gabapentin [28] and has been recently marketed in several countries for the treatment of neuropathic pain [6 ] . Although gabapentin and pregabalin were first identified as treatments for neuropathic pain, a condition previously thought to be entirely distinct from inflammatory pain [29] , early preclinical studies suggesting analgesic efficacy following tissue injury [30] have led to the development of gabapentin and pregabalin as treatments for postsurgical pain [10] . With the first published gabapentin analgesic RCTs in 1998 [26, 27] and the first published pregabalin analgesic RCT in 2001 [31] , it should be noted that the evidence base supporting the use of gabapentin and pregabalin for pain management is less than a decade old, with many important questions yet to answer.
Pharmacological effects and analgesic mechanisms
Previous studies suggest that gabapentin may have important actions at peripheral [32] , primary afferent neuron [33] , spinal cord [34] and supraspinal [35] sites. Reviews based upon numerous laboratory investigations indicate that gabapentin and pregabalin produce several pharmacological effects, including competition with other amino acids for membrane transport across the 'L-alpha-amino acid transporter system', increasing the concentration of GABA in the brain, activation of ATPsensitive Kþ channels and hyperpolarization-activated cation channels, activation of heterodimeric GABA-B receptors, and binding to the alpha-2-delta subunit of N-type voltage-gated calcium channels [36, 37 ] . Recent compelling evidence suggests that binding of gabapentin and pregabalin to the alpha-2-delta subunit of N-type voltage-gated calcium channels is likely the most important analgesic mechanism of these drugs [37 -39 ] . In particular, nerve injury in rats results in upregulation of alpha-2-delta-1 calcium channel subunits in dorsal root ganglion neurons [40, 41] and this upregulation has been shown to correlate with the antinociceptive effects of gabapentin [42] . More recent work suggests that, unlike normal 'wild-type' mice, 'R217A' mutant mice -that exhibit decreased pregabalin binding at alpha-2-delta-1 calcium channel subunits -show no antinociceptive response to gabapentin or pregabalin following nerve injury, but do respond to treatment with amitriptyline [38 ] . Of further interest, pregabalin (but not morphine) was ineffective in reducing pain behaviors in 'R217A' mutant mice following formalin injection, which is a nociceptive pain model [38 ] . Taken together, these results suggest that -in both neuropathic and posttissue injury pain -binding to alpha-2-delta calcium channel subunits is likely an important mechanism for the analgesic effects of gabapentin and pregabalin. Alpha-2-delta calcium channel subunit binding is thought to then result in a reduction in the release of neurotransmitters such as glutamate [43] and substance P [44] , thus suppressing neuronal excitability following nerve or tissue injury. It should be emphasized that one of the key features of these drugs is that their antinociceptive effects occur primarily in the setting of neural sensitization after nerve or tissue injury and that they have minimal effects on normal physiological pain transmission [39 ] .
While 'alpha-2-delta' binding is currently thought to be the most important mechanism, one cannot rule out the possibility that other important analgesic mechanisms of gabapentin and pregabalin have yet to be described. For example, a recent translational study demonstrated important interactions between gabapentin and spinal alpha-2-adrenergic receptor systems in the rat and, furthermore, that gabapentin administration reduces cerebrospinal fluid norepinephrine levels in humans [45 ] . Taken together, results from these and other studies suggest the possibility of important interactions between gabapentin or pregabalin and modulators of adrenergic neurotransmission. Readers are encouraged to consult previous reviews on the antinociceptive effects of gabapentin and pregabalin described in various preclinical pain models [6 ,37 ,39 ] .
Clinical pharmacology
Basic information about the clinical pharmacology of gabapentin and pregabalin is listed in Table 2 but, of course, health professionals are urged to review the product monographs before prescribing these Gabapentin and pregabalin Gilron 457 Gabapentin Neuropathic and postsurgical medications. The lack of hepatic enzyme inhibition or induction and the lack of clinically important drug interactions are major perceived advantages of gabapentin and pregabalin [46, 48] . Oral antacids, however, are known to diminish the bioavailability of gabapentin by 20-30% [46] . As with other sedating drugs, gabapentin and pregabalin can potentiate the effects of other sedatives such as ethanol and benzodiazepines. Doses of both drugs should be reduced proportional to creatinine clearance in the presence of renal insufficiency since they are normally excreted unchanged in the urine [46, 48] . Absorption of pregabalin is quite fast (approximately 1 h to maximal absorption) and oral bioavailability remains very high (>90%) regardless of dose. In contrast, absorption of gabapentin is slightly slower (2-3 h to maximal absorption) and occurs through a saturable transport system in the gastrointestinal tract, such that bioavailability decreases with increasing doses [50] . Therefore, gabapentin dose increases in higher dose ranges should be expected to lead to incrementally smaller increases in plasma drug concentrations (i.e. nonlinear pharmacokinetics). RCTs of gabapentin and pregabalin have used starting doses of at least 300 mg/day and 75 mg/day, respectively (see below). In the elderly, however, in patients with renal insufficiency, or in patients already receiving sedating drugs, one should consider starting with even lower doses than these and titrating the dose very slowly in order to minimize the risk of falling and related trauma. Usual effective, and tolerable, doses for neuropathic pain range from 1200 to 2400 mg/day for gabapentin and 150 to 600 mg/day for pregabalin, and doses greater than 3600 mg/day and 600 mg/day, respectively, have not been studied (Table 2) .
Neuropathic pain
The topic of neuropathic pain can be further considered under the headings diabetic neuropathy, postherpetic neuralgia, and other neuropathic pain syndromes.
Diabetic neuropathy
Three gabapentin and three pregabalin placebocontrolled RCTs in diabetic peripheral neuropathy (DPN), as well as one nonplacebo-controlled trial comparing gabapentin only to amitriptyline, have been published (Table 3) . Also, one gabapentin RCT and one pregabalin RCT involving a mixed population of 60-70% DPN and 30-40% postherpetic neuralgia (PHN) patients are outlined in Table 4 .
In two of the four placebo-controlled gabapentin RCTs, analgesic efficacy was statistically superior to placebo and was accompanied by improvements in several secondary measures of quality of life, mood and sleep [26, 53] . In an industry-sponsored RCT, Backonja et al. reported a 39% pain reduction from baseline with gabapentin, significantly greater than the 22% pain reduction seen with placebo [26] . Another trial reported a 38% pain reduction from baseline with gabapentin, significantly greater than the 8% pain reduction seen with placebo [53] . The symbol '>' denotes 'analgesic efficacy greater'; listed differences were reported as statistically significant unless otherwise stated.
Three industry-sponsored RCTs of pregabalin for pain in DPN have been published. These RCTs (see Table 3 ) report superiority over placebo with 34-40% pain reductions from baseline at pregabalin target doses of at least 300 mg/day [54] [55] [56] . In these RCTs, pain reduction was accompanied by improvements in sleep over similar dosage ranges and with a similar temporal profile [54] [55] [56] . The mixed DPN/PHN pregabalin RCT reported similar results [58] (Table 4 ).
Postherpetic neuralgia
In the setting of PHN treatment, two gabapentin and three pregabalin RCTs, as well as one nonplacebocontrolled trial comparing gabapentin only to nortriptyline, have been published (Table 5 ).
Gabapentin was studied in 336 PHN patients in two industry-sponsored RCTs that demonstrated analgesic efficacy at target doses of 1800, 2400 or 3600 mg/day [27, 59] (see Table 5 ). Pain reduction from baseline was reported to be 33-35% in all three of these dose groups. Improvements in sleep and several SF-36 quality of life domains were also reported [27, 59] .
Efficacy of pregabalin in PHN was reported in three large industry-sponsored RCTs [61,62,63 ] (see Table 5 ), with pain reductions from baseline that varied from 18% at 150 mg/day [63 ] to 37% at 600 mg/day [61] . Pain relief, again, was accompanied by improved sleep over similar dosage ranges and with a similar temporal profile.
Other neuropathic pain syndromes
Since not all drugs effective in DPN or PHN are effective in other neuropathic syndromes [1,64 ], investigators have formally evaluated gabapentin and pregabalin in other neuropathic pain conditions (Table 6) .
Pain reduction with gabapentin was reported to be superior to placebo in RCTs of phantom limb pain [68] , Guillain-Barré syndrome [72, 73] , cancer-related neuropathic pain [74] and mixed neuropathies [71] . Levendoglu et al. [66] reported a positive result in spinal cord injured (SCI) patients whereas a smaller SCI trial failed to show significant differences in pain intensity, possibly due to inadequate statistical power [65] . Gabapentin appeared to demonstrate slight, statistically insignificant superiority over placebo in a single RCT of patients with complex regional pain syndrome (CRPS) type I [67] . In a small RCT (n ¼ 11-15 per group) of human immunodeficiency virus (HIV)-associated neuropathy, pain reduction from baseline was reported as 44.1% with gabapentin and 29.8% with placebo. The gabapentin-placebo difference in pain reduction was not statistically significant, however [69] . In a recent randomized, open-label spinal stenosis study, gabapentin in addition to standard therapy (exercise, corset brace and NSAIDs) resulted in greater walking distance and less pain compared with standard therapy alone [70 ] .
In a recent industry-sponsored trial of pregabalin for central neuropathic pain following spinal cord injury, analgesic efficacy was superior to placebo, and additional reported benefits included reduced anxiety and improved sleep [75 ] .
Comparative and combination trials
A small number of RCTs have compared gabapentin with other drugs for neuropathic pain. At the time of writing, 460 Pain medicine Flex, flexible dose titration to maximally tolerated dose; Fixed, forced titration to maximal target dose; Plc, placebo; SSRIs, selective serotonin reuptake inhibitors; ASA, aspirin; Prev Gbp, previous gabapentin exposure; MTD, maximally tolerated dose; BID, twice daily; NRS, numerical rating scale; NS, not statistically significant; SF-MPQ, Short Form McGill Pain Questionnaire; AEs, adverse events. Trial quality score, see text for details. Modified from [6 ] . a The symbol '>' denotes 'analgesic efficacy greater'; listed differences were reported as statistically significant unless otherwise stated. The symbol '>' denotes 'analgesic efficacy greater'; listed differences were reported as statistically significant unless otherwise stated.
no comparative RCTs of pregabalin have been published. Gilron et al. [57] demonstrated that neuropathic pain intensity was significantly lower during treatment with morphine-gabapentin combination than with gabapentin alone. In addition, a trend favoring morphine alone over gabapentin alone was observed, and the efficacy of morphine, but not gabapentin, was statistically superior to placebo [57] . In a small second-phase study of 11 gabapentin nonresponders, a venlafaxine-gabapentin combination was superior to gabapentin alone [53] . In a nonplacebo-controlled trial, Morello et al. [52] reported a nonsignificant trend favoring amitriptyline slightly over gabapentin. Finally, in a more recent PHN trial, efficacy of gabapentin was reported to be comparable with that of nortriptyline; however, gabapentin was reportedly better tolerated [60 ] .
Early postsurgical pain
At the time of writing, gabapentin has been studied in 901 surgical patients as described in 11 RCTs of abdominal or pelvic surgery (Table 7) , 10 RCTs of musculoskeletal surgery (Table 8) , and six RCTs of head, neck and breast surgery ( Table 9 ). Seventeen of all presented trials evaluated only single preoperative doses of gabapentin and the remaining 10 evaluated repeated doses of gabapentin over periods of 1-10 days. Most trials started gabapentin administration before surgery; however, a recent trial in donor nephrectomy patients showed no statistically significant difference in pain scores upon comparing preoperative with postincisional administration [81] . Presented RCTs evaluated variable gabapentin doses from as low as single doses of 300 mg to as high as 1800 mg/day. Although further work is needed to better define the optimal gabapentin dose for specific surgical procedures and at different postoperative timepoints, it is useful to note that Pandey and colleagues conducted a doseresponse trial of gabapentin single-dose pretreatment in lumbar discectomy patients. This study demonstrated an analgesic ceiling at 600 mg, that is, pain reduction with 600 mg was better than with 300 mg but no additional benefits were observed at doses of 900 or 1200 mg [89] . [82] . Cumulative morphine consumption was similarly reduced in both single agent gabapentin and rofecoxib groups, with even further significant reductions seen in the combination group. Pain evoked by cough was roughly similar in both gabapentin and rofecoxib groups. Finally, Durmus and colleagues have recently shown that combining acetaminophen with gabapentin significantly reduces postoperative pain and opioid consumption when compared with gabapentin alone [86 ] .
In light of gabapentin's known anxiolytic effects [103, 104] , it is also interesting to note that one perioperative trial showed an anxiolytic effect with gabapentin in the setting of knee surgery [91] . Also, whether related to opioid sparing or a specific antiemetic effect, one trial has suggested that gabapentin may reduce nausea and vomiting following laparoscopic cholecystectomy [105 ] . Following previous suggestions that lower movementevoked pain correlates with improved postoperative function [106] , it is interesting to note that, in the setting of anterior cruciate ligament repair, preoperative gabapentin administration resulted in greater knee flexion angles on postoperative days 1 and 2 [91] . Furthermore, Gilron et al. demonstrated that lung function during treatment with either gabapentin or rofecoxib, as assessed by peak expiratory flow rate, was significantly higher than with placebo, and these improvements were enhanced even further when both drugs were given in combination [82] . These observations indicate that gabapentin-induced reductions in movement-evoked pain may actually accelerate postoperative functional recovery. Future investigations with longer follow-up and more specific outcome measures are needed, however, in order to determine whether these benefits translate into lower complication rates, earlier hospital discharge or earlier return to work. Also, given the hypothesis that more effective pain management may prevent chronic postsurgical pain [107] , a trial of 10 days of gabapentin treatment (1200 mg/day) following breast cancer surgery reporting lower chronic postsurgical pain may have generated much excitement [98] . A more recent RCT of 30 days of gabapentin treatment (up to 2400 mg/day) following lower limb amputation failed, however, to demonstrate any reduction in the incidence or intensity of postamputation pain [108 ] .
Based on published RCTs at the time of writing, pregabalin has been studied in 173 surgical patients (Table 10 ).
Gabapentin and pregabalin Gilron 463 In an oral surgery analgesic trial, 300 mg of pregabalin provided a significantly higher pain intensity difference than placebo [31] , with a slightly lower peak effect but longer duration of action than the trial's active comparator, ibuprofen 400 mg [31] . Doses of 150 mg of pregabalin reduced both pain and opioid consumption (compared with placebo) following spinal surgery and observed efficacy was further enhanced with the addition of celecoxib [109 ] . In a recent RCT of patients receiving oxycodone, paracetamol and ibuprofen following laparoscopic hysterectomy, pregabalin 600 mg (but not 300 mg) resulted in significantly less opioid consumption than the active placebo, diazepam, but mean pain scores were similar across all treatment groups and varied between only 0.5 and 1.5 on an 11-point VAS scale [110 ] .
Gabapentin and pregabalin for the treatment of other pain syndromes
Although the focus of this review and the great majority of pain-related treatment studies deal with chronic neuropathic and early postsurgical pain, gabapentin and pregabalin are being studied for the treatment of various other pain conditions. Examples of other pain conditions that may respond to these drugs include chronic daily headache [111] , fibromyalgia [112, 113 ] , acute herpes zoster pain [114] , chronic pelvic pain [115] and orofacial muscle pain [116 ] .
Safety and tolerability of gabapentin in chronic neuropathic pain
Gabapentin is considered a relatively safe and well tolerated drug after over a decade of marketing and widespread international use. Despite the challenges in demonstrating treatment-related causality with observed adverse events, several adverse event reports involving gabapentin bear mentioning. Several case reports have described various adverse events following abrupt [117] [118] [119] [120] or even tapered [121] withdrawal of gabapentin, including tachycardia, diaphoresis, headache, gastrointestinal cramps, catatonia and, in one case, status epilepticus in the absence of a preexisting seizure disorder [119] .
Other reports suggest the possibility that gabapentin induces various movement disorders, including myoclonus, dystonia and asterixis [122] [123] [124] [125] [126] , which may be a cause of falls [126] . Two different case reports have suggested that gabapentin may exacerbate myasthenia gravis [127, 128] . Single case reports have implicated gabapentin as contributing to psychomotor agitation [129] , renal allograft dysfunction [130] , amenorrhea [131] , arthralgia [132] , aggressive behavior in children [133] , painful gynecomastia [134] , cutaneous leukocytoclastic vasculitis [135] and neutropenia [136] . Table 11 describes adverse event frequencies from several published gabapentin RCTs in neuropathic pain. As with the treatment of epilepsy [137] , these data indicate that the most common adverse effects of gabapentin are somnolence, dizziness and ataxia. These symptoms are generally dose-related and reversible following dose reduction. Other signs or symptoms reported in more than 10% of patients, in at least two RCTs, include peripheral edema, lethargy, headache and diarrhea (see Table 11 ). These events were not, however, necessarily significantly more frequent than with placebo. Of relevance to patients with painful diabetic neuropathy, gabapentin treatment did not appear to adversely affect glycemic control in diabetic patients [26] .
Gabapentin and pregabalin Gilron 465 ns, not statistically significant; þ indicates significant pain intensity difference between gabapentin and placebo groups; 0 indicates no significant pain intensity difference between gabapentin and placebo groups. a Refers only to gabapentin-placebo comparison and refers to pain at rest unless otherwise specified.
Safety and tolerability of pregabalin in chronic neuropathic pain
Being a newer drug, fewer postmarketing safety data are available for pregabalin. As with gabapentin, the most frequent adverse events described with pregabalin include somnolence, dizziness, ataxia and peripheral edema [138] . Pregabalin, too, has been implicated in the onset of movement disorders such as myoclonus [139] and asterixis [140] , and a single case report has described encephalopathy and edema of the splenium of the corpus callosum following abrupt discontinuation of pregabalin [141] . Limited evidence suggesting subjective drug 'liking' in a study of pregabalin in recreational sedative/hypnotic drug users, as well as withdrawal symptoms upon pregabalin discontinuation, have led the US Drug Enforcement Administration to list pregabalin as a Schedule V narcotic of the Controlled Substances Act (low potential for abuse) [138] . Less than 5% of patients from all pregabalin RCTs reported euphoria as an adverse event, however. Table 12 shows reported frequencies of adverse effects from several pregabalin RCTs in neuropathic pain. Data suggest that, as with gabapentin, the most common adverse effects of pregabalin are somnolence, dizziness and peripheral edema. In at least two RCTs, various other adverse events have been reported in more than 10% of patients, including headache, weight gain and dry mouth (see Table 12 ). These events were not necessarily significantly more frequent than with placebo, however. Pregabalin, too, did not appear to adversely affect glycemic control in diabetic patients [55] .
Safety and tolerability of gabapentin and pregabalin in early postsurgical pain
Three gabapentin trials did not formally report on adverse effects [84 ,98,100] , and 16 RCTs reported no significant difference in side effects between gabapentin and placebo (see Tables 7-9 ). It should be emphasized, however, that given variable methods of assessment, most trials were not statistically powered to detect such differences in adverse effects. More frequent sedation was reported with gabapentin in three trials [80, 82, 99] ; more nausea was reported with gabapentin in one trial [80] , more dizziness in two RCTs [95 ,102 ] , and gait disturbance and vomiting were reported more frequently with gabapentin in one trial [102 ] . Single RCTs reported that, compared with placebo, gabapentin was associated with less frequent vomiting [88] , urinary retention [88] , postoperative delirium [93 ] and headache [94 ] . It should be noted that only one of the 21 RCTs showing opioid sparing also reported a reduction in opioid-related side effects [88] . Several trials reported no significant differences between gabapentin and controls with respect to heart rate, blood pressure or respiratory rate during the postoperative period [78,86 ,88] . Fassoulaki et al. reported that 400 mg of gabapentin blunted the blood pressure, but not the heart rate, increase during laryngoscopy [142 ] , whereas Memis et al. reported that 800 mg blunted both blood pressure and heart rate increases during laryngoscopy [143 ] .
Of the three postoperative pregabalin RCTs, two reported no significant difference in adverse effects [31, 109 ] . The third RCT of pregabalin 300 and 600 mg following laparoscopic hysterectomy reported more frequent headache, dizziness and blurred vision and less frequent pruritus [110 ] . Reuben et al. reported no significant differences between pregabalin and controls with respect to heart rate, blood pressure or respiratory rate during the postoperative period [109 ] .
Summary: chronic neuropathic pain
From the trials listed in Tables 3 -6 , gabapentin was studied in a total of 1022 patients and pregabalin was studied in a total of 1341 patients. Only five of the 18 gabapentin trials and none of the pregabalin trials presented were unable to demonstrate a difference ns, not statistically significant; Pgb, pregabalin; Plc, placebo; þ indicates significant pain intensity difference between gabapentin and placebo groups; 0 indicates no significant pain intensity difference between gabapentin and placebo groups. a Refers only to gabapentin-placebo comparison and refers to pain at rest unless otherwise specified. between active treatment and control. Two of the negative gabapentin trials were very small studies [65, 69] : one used only 900 mg/day [51] ; one used lorazepam as an active placebo and showed important differences in multiple secondary pain outcomes [57] , and one involved patients with CRPS type 1 [67] . 
Summary: early postsurgical pain
As can be appreciated by several recent postoperative meta-analyses (Table 1) , drawing broad-ranging conclusions on the clinical utility of gabapentin and pregabalin for postoperative pain is currently very challenging, due to heterogeneity of available RCTs with respect to surgical procedure and patient population, trial design and quality, outcome measures used, drug dose and duration of treatment. Nevertheless, a majority (21 of 30) of published placebo-controlled, doubleblind, randomized trials have demonstrated postoperative analgesic efficacy with gabapentin and pregabalin, and a small number of comparative trials suggest that their analgesic and opioid-sparing efficacy is roughly comparable with that of nonsteroidal anti-inflammatory drugs [82,83 ,109 ] and is perhaps superior to mexiletine [98] , acetaminophen [98] and tramadol [80] . An important feature of gabapentin and pregabalin is their efficacy for movement-evoked pain which, in some studies, was associated with accelerated postoperative functional recovery [82, 91] . Sedation or dizziness occurred more frequently with gabapentin or pregabalin in six of 30 trials [80,82,95 ,99,102 ,110 ] . Although the majority of trials (22 of 30) reported opioid-sparing effects with gabapentin or pregabalin, only one of these trials reported a concurrent reduction in opioid-related adverse effects [88] .
Conclusion
Multiple, large high-quality RCTs have demonstrated the safety and efficacy of gabapentin and pregabalin in neuropathic pain, leading to their recommendation as first-line neuropathic pain treatments by several experts [1, 64 ,144,145 ,146 ] . Improvement of neuropathic pain and sleep with gabapentin or pregabalin has been shown to positively impact upon quality of life. Sedation, dizziness and ataxia are important and relatively common adverse effects of these drugs, however. Patients suffering from neuropathic pain might benefit from additional research, which addresses several questions. For example, how do gabapentin and pregabalin compare with each other and to other neuropathic pain treatments? What is the efficacy of pregabalin in neuropathic pain conditions other than DPN and PHN? How do gabapentin and pregabalin interact with other neuropathic pain drugs in the setting of analgesic polypharmacy for neuropathic pain? What is the analgesic efficacy and safety of these drugs in special populations (e.g. children, pregnancy/lactation, elderly etc.)? Can novel preparations (e.g. sustained-release) of gabapentin/pregabalin or perhaps even other novel 'alpha-2-delta ligands' improve the current treatment of neuropathic pain? Are gabapentin and pregabalin effective analgesics for other nonneuropathic chronic pain conditions?
Contrary to previous beliefs that posttissue injury pain and chronic neuropathic pain are entirely separate entities, accumulating evidence indicates that anticonvulsants such as gabapentin and pregabalin actually have important analgesic effects following surgery [11 ] .
Multiple high-quality (but relatively smaller-sized) RCTs have demonstrated analgesic and opioid-sparing efficacy following a wide variety of surgical procedures. An important benefit of treatment with gabapentin or pregabalin is the reduction of movement-evoked pain that has been related to acceleration of functional postoperative recovery. Postoperative opioid sparing with gabapentin/pregabalin is of questionable clinical relevance since very few RCTs have shown any reduction in opioid-related adverse effects. Sedation, dizziness and gait disturbances have been reported in only a small proportion of published RCTs. Broad-ranging conclusions on the perioperative safety of gabapentin/pregabalin cannot be made, however, because of the safety assessment methods and small RCT sizes available.
It is well recognized that selection of postoperative analgesic treatment regimens depends largely on the type of surgery [147] . Given the variable degrees of tissue injury, physiological impact and analgesic response across different surgical procedures, it has been suggested that pooled efficacy estimates for a given analgesic treatment (e.g. number-needed-to-treat) should be related to specific surgical procedures [148] . Thus, given the heterogeneity and relatively small sizes of published RCTs, future efforts should be directed towards larger multicenter trials of gabapentin or pregabalin, following specific procedures where these drugs may have maximal impact with a major focus on safety, efficacy and functional recovery. Since the sedating effects of gabapentin/ pregabalin may be partially mitigated by opioid sparing, administration of gabapentin/pregabalin would be best suited for procedures, and at postoperative timepoints, normally associated with substantial opioid administration. Surgical patients might benefit from additional research that addresses several other questions. For example, what is the optimal dose of, and duration of treatment with, gabapentin/pregabalin for the treatment of postoperative pain? Does gradual (i.e. over days to weeks) dose-titration towards maximal doses of gabapentin/pregabalin (e.g. 3600/600 mg/day) improve postoperative analgesic efficacy? How does preoperative gabapentin/pregabalin administration interact with intraoperative anesthetics and analgesics? How do gabapentin/pregabalin interact with other nonopioid analgesics in the setting of postoperative multimodal therapy? What is the feasibility and potential added benefit of human administration of gabapentin/pregabalin via other routes of administration (e.g. intravenous, intrathecal, epidural etc.)? How does perioperative administration of gabapentin/pregabalin affect postsurgical functional recovery? Can perioperative treatment with gabapentin/pregabalin reduce the incidence or severity of chronic postsurgical pain?
Gabapentin and pregabalin bind to the alpha-2-delta subunit of voltage-gated calcium channels and represent a novel class of drugs for the treatment of neuropathic and postsurgical pain. Perhaps the greatest advantage of these drugs is their relative safety, tolerability and ease of use, as well as lack of adverse interactions with other medications. Furthermore, emerging evidence suggests that gabapentin and pregabalin may also be useful for other acute and chronic pain conditions. Further research is needed to better delineate the optimal utility of these drugs for other indications. 
